Sangamo Therapeutics (SGMOQ) Tax Provisions (2015 - 2025)
Sangamo Therapeutics (SGMOQ) posted Tax Provisions of -$553000.0 for Q4 2025, down 243.48% on a QoQ basis from -$161000.0 in Q3 2025, and down 29.51% year-over-year from -$784488.4 in Q4 2024.
Powered by 
Analysis
Sangamo Therapeutics (SGMOQ) Tax Provisions (2015 - 2025) Analysis & Trends
Sangamo Therapeutics has reported Tax Provisions for 8 years, with the latest figure at -$553000.0 in Q4 2025.
- On a quarterly basis, Tax Provisions fell 29.51% year-over-year to -$553000.0 in Q4 2025; TTM through Dec 2025 was -$568000.0, a 240.12% decrease from a year earlier, with the FY2025 full-year figure at -$568000.0, down 240.12% from the prior year.
- Tax Provisions was -$553000.0 for Q4 2025 at Sangamo Therapeutics, down from -$161000.0 in the prior quarter.
- The five-year high for Tax Provisions was $1.3 million in Q3 2023, with the low at -$6.3 million in Q2 2023.
- Average Tax Provisions over 5 years is -$253700.0, with a median of $78000.0 recorded in 2022.
- The largest YoY upside for Tax Provisions was 4133.33% in 2023 against a maximum downside of 7739.02% in 2023.
- Over 5 years, Tax Provisions stood at -$94000.0 in 2021, then soared by 343.62% to $229000.0 in 2022, then tumbled by 218.78% to -$272000.0 in 2023, then tumbled by 56.99% to -$427000.0 in 2024, then retreated by 29.51% to -$553000.0 in 2025.
- The last three Tax Provisions figures came in at -$553000.0 (Q4 2025), -$161000.0 (Q3 2025), and $27000.0 (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.20 Bn | 9.36 Bn | 112.79 Mn | 11.31 Mn |
| 2 | CRISPR Therapeutics AG | 5.20 Bn | 5.20 Bn | - | 1.00 Mn |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.50 Bn | 55.72 Mn | -1.40 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.72 Bn | 251.50 Mn | -22.30 Mn |
| 5 | uniQure | 3.07 Bn | 3.07 Bn | 5.49 Mn | 1.84 Mn |
| 6 | Beam Therapeutics | 2.67 Bn | 2.67 Bn | - | - |
| 7 | Precigen | 2.43 Bn | 2.43 Bn | 52.17 Mn | - |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.54 Bn | 251.87 Mn | 3.14 Mn |
| 9 | Vericel | 2.00 Bn | 1.84 Bn | 56.40 Mn | - |
| 10 | Sangamo Therapeutics | 43.15 Mn | 22.20 Mn | - | -553,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -553,000.00 |
| Sep 30, 2025 | -161,000.00 |
| Jun 30, 2025 | 27,000.00 |
| Mar 31, 2025 | 119,000.00 |
| Dec 31, 2024 | -427,000.00 |
| Sep 30, 2024 | 88,000.00 |
| Jun 30, 2024 | 74,000.00 |
| Mar 31, 2024 | 98,000.00 |
| Dec 31, 2023 | -272,000.00 |
| Sep 30, 2023 | 1.27 Mn |
| Jun 30, 2023 | -6.26 Mn |
| Mar 31, 2023 | 194,000.00 |
| Dec 31, 2022 | 229,000.00 |
| Sep 30, 2022 | 30,000.00 |
| Jun 30, 2022 | 82,000.00 |
| Mar 31, 2022 | 100,000.00 |
| Dec 31, 2021 | -94,000.00 |
| Sep 30, 2021 | 100,000.00 |
| Jun 30, 2021 | 24,000.00 |
| Mar 31, 2021 | 262,000.00 |